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The lung microbiome, which is believed to be stable or at least transient in healthy
people, is now considered as a poly-microorganism component contributing to disease
pathogenesis. Most research studies on the respiratory microbiome have focused on
bacteria and their impact on lung health, but there is evidence that other non-bacterial
organisms, comprising the viruses (virome) and fungi (mycobiome), are also likely to
play an important role in healthy people as well as in patients. In the last few years,
the lung mycobiome (previously named the fungal microbiota or microbiome) has drawn
closer attention. There is growing evidence that the lung mycobiome has a significant
impact on clinical outcome of chronic respiratory diseases (CRD) such as asthma, chronic
obstructive pulmonary disease, cystic fibrosis, and bronchiectasis. Thanks to advances in
culture independent methods, especially next generation sequencing, a number of fungi
not detected by culture methods have been molecularly identified in human lungs. It has
been shown that the structure and diversity of the lung mycobiome vary in different
populations (healthy and different diseased individuals) which could play a role in CRD.
Moreover, the link between lung mycobiome and different biomes of other body sites,
especially the gut, has also been unraveled. By interacting with the bacteriome and/or
virome, the respiratory mycobiome appears to be a cofactor in inflammation and in the
host immune response, and therefore may contribute to the decline of the lung function
and the disease progression. In this review, we report the recent limited explorations of
the human respiratory mycobiome, and discuss the mycobiome’s connections with other
local microbial communities, as well as the relationships with the different biomes of other
body sites. These studies suggest several outlooks for this understudied emerging field,
which will certainly call for a renewal of our understanding of pulmonary diseases.
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INTRODUCTION
The recent use of culture-independent microbiological techniques
based on deep-sequencing has shown that the respiratory tract of
healthy people are not sterile as formerly thought, but composed
of a previously unappreciated complex microbial community
referred as the microbiome (Charlson et al., 2010; Erb-Downward
et al., 2011). In particular, two international projects were recently
launched: the American Human Microbiome Project (HMP)1
and the European Metagenomics of the Human Intestinal Tract
(MetaHit2; The NIH HMP Working Group et al., 2009; Hutten-
hower et al., 2012). They first aimed to characterize the nature,
composition, and diversity of normal and pathological bacteri-
omes (bacterial microbiomes) at different body sites including
the nasal passages, oral cavities, skin, gastrointestinal tract, and
urogenital tract. The respiratory tract was secondarily included
1http://www.hmpdacc.org/
2http://www.metahit.eu/
in the American program as a body site, and the lung micro-
biome has become a new attractive and rapidly growing field of
research. However, the majority of these lung microbiome studies
have focused on bacteria; the characterization of viral or fungal
microbiomes—also referred as the virome and mycobiome—has
not been closely investigated. It is commonly accepted that a given
microbial community associated with host tissues or organs is
known as the “biota,” while the whole genome collection of this
microbial community is mentioned as the “biome.” Accordingly,
“mycobiota” refers to the fungal component of a given microbial
community, and the corresponding genomes are referred to as
the “mycobiome” (Hooper, 2001; Iliev et al., 2012; Orgiazzi et al.,
2013).
While the concept of the human mycobiome has been empha-
sized in the past few years (Cui et al., 2013; Huffnagle and
Noverr, 2013), little is known about the human mycobiome in
general, and the lung mycobiome in particular as confirmed by
our search in PubMed of the terms: “mycobiota,” “mycobiome,”
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“human mycobiota,” “human mycobiome,” “mycobiome AND
lungs,” “mycobiota AND lungs,” “human mycobiome AND
lungs,” “human microbiota and lungs,” “fungal microbiome
AND lungs” that appeared respectively in 190, 29, 49, 24, 272, 1,
188, 213, and 146 publications. With or without using these spe-
cific keywords, a total of 67 research publications and 29 reviews
were relevant to the purpose of our review. Lung mycobiome
research is clearly an “emerging world” as recently proposed
(Huffnagle and Noverr, 2013), for which the growing scientific
interest is supported by several reasons.
First, the human respiratory tract represents the main portal
of entry for numerous microorganisms primarily those occurring
as airborne particles such as viruses, bacteria, or fungi. Fungal
spores are representing more than 50,000 spores per cubic meter
of air during the fungal season (Pashley et al., 2012; Denning
et al., 2014). The corresponding microorganism characteristics,
coupled with the local immune response will determine whether
they will be cleared or adhere to and colonize the respiratory tract,
leading to pulmonary diseases (or their infectious complications).
Although the total number of fungal cells is smaller than that of
the bacteria, nobody is fungus-free (Huffnagle and Noverr, 2013).
Second, mycosis represents an emergent threat to public
health, which has increased not only in width, but also in depth.
Whereas fungal pulmonary infections represent life-threatening
diseases in patients in a comparable rate to the mortality
attributable to tuberculosis or malaria, it is still difficult to
diagnose and treat them. Beside the most prevalent and well-
known fungal pathogens such as Candida albicans and Aspergillus
fumigatus, a large number of new emerging pathogens have been
described (Horré et al., 2010; Fisher et al., 2012; Marguet et al.,
2012). In addition, the widespread use of antibiotics has probably
influenced the balance between bacterial and fungal infections
facilitating the occurrence of respiratory mycosis that are becom-
ing resistant to antifungal drugs and difficult to treat (Chen et al.,
2012; Vermeulen et al., 2013; Bousquet et al., 2014).
Third, common links exist between fungi and diseases such
as chronic respiratory diseases (CRD) through the immunogenic
background of each individual. As part of the continuous host–
pathogen–environment interaction from birth to death, fungi
have been associated with asthma, chronic obstructive pulmonary
disease (COPD), cystic fibrosis (CF), bronchiectasis at different
levels (such as fungal isolation in a sputum sample, sensitization
to A. fumigatus or to other fungi; Fillaux et al., 2012; Knutsen
et al., 2012; Speirs et al., 2012; Armstead et al., 2014; Denning
et al., 2014). The presence of fungi in respiratory tract also related
to worse CRD outcome (Amin et al., 2010; Chotirmall et al.,
2010).
Despite the fact that knowledge of the mycobiome lags behind
our understanding of the bacterial microbiome, specific myco-
biota have been identified in pulmonary diseases as well as in
oral, digestive, and skin diseases (Ghannoum et al., 2010; Lu et al.,
2011; Charlson et al., 2012b; Delhaes et al., 2012; Knutsen et al.,
2012; Harrison et al., 2013; Huang et al., 2013; Dupuy et al.,
2014; Willger et al., 2014). Currently, the abundance of fungi
in different body sites seems to be many degrees smaller than
bacteriome as recently reported (Marsland and Gollwitzer, 2014;
Underhill and Iliev, 2014). For example, gut mycobiome has been
evaluated at less than 0.1% in human feces upon the MetaHIT
project (Huffnagle and Noverr, 2013). Since the development of
the host immune system depends on its symbiotic relationship
with the microbiome, the mycobiome may act as a cofactor
in the lung inflammatory response (Marsland and Gollwitzer,
2014). Therefore, it appears to be essential to understand more
about respiratory mycobiome, and its potential interaction with
other biomes in order to get a complete picture of the lung
microbiome and to improve patient management by changing
current paradigms of the disease.
In this review, we summarize the recent advances in charac-
terizing the respiratory mycobiome of patients with CRD, and
discuss the mycobiome’s connections with other local micro-
bial communities, as well as the relationships with the different
biomes of other body sites. These studies suggest several outlooks
for this emerging field which will certainly call for a renewal of
our understanding of pulmonary diseases.
RESPIRATORY MYCOBIOME: FROM PROOF OF CONCEPT
TO RATIONAL DATA
Conventional microbial methods such as cultures of respira-
tory samples are useful in diagnosing fungal infections and to
isolating and phenotyping microorganisms. However, they have
some limitations in identifying co-infections and dynamics of
polymicrobial populations. These communities consist of bacte-
ria, fungi, and viruses all potentially contributing to infection and
inflammation (Lu et al., 2011; Charlson et al., 2012a,b; Delhaes
et al., 2012; Fodor et al., 2012; Filkins et al., 2012; Carmody
et al., 2013; Cui et al., 2013; Harrison et al., 2013; Huang et al.,
2013; Dawood et al., 2014; Fitzpatrick et al., 2014; Goffard et al.,
2014; Lim et al., 2014; McCullers, 2014; Mounier et al., 2014;
Purcell et al., 2014; Willger et al., 2014; Wurzel et al., 2014).
In addition, the majority of fungal species are difficult to cul-
tivate or uncultivable on usual culture media as well as new or
unknown pathogens (Bittar et al., 2008; Chabé et al., 2011; Paniz-
Mondolfi et al., 2012). In this context, deep-sequencing methods
provide an indisputable possibility to identify all microbial species
(including those difficult to culture) and to generate exhaustive
microbial community data. Despite recent efforts to develop high-
throughput methods targeting fungal ribosomal RNA genes to
characterize fungal microbiota (recently summarized by Cui et al.
(2013), the published data have mainly explored the lung bacte-
riome. Only few studies have addressed respiratory community
and diversity of fungi (Charlson et al., 2012a,b; Delhaes et al.,
2012; Harrison et al., 2013; van Woerden et al., 2013; Willger
et al., 2014) or viruses and phages (Willner et al., 2011, 2012; Lim
et al., 2013). But there is growing evidence to suggest the impact
of viral infection on pulmonary exacerbation, and mold-related
respiratory effects on CRD (Reponen et al., 2011, 2012; Hulin
et al., 2013; Kieninger et al., 2013).
Briefly, each lung microbiota (including mycobiota) has its
own composition and evolution, which is unique and specific to
each individual. It probably evolves according to the pulmonary
disease and to the occurrence or not of an acute pulmonary
exacerbation (Fodor et al., 2012; Carmody et al., 2013; Lim et al.,
2014; Willger et al., 2014). As a consequence it is believed to play
a role in the alteration of the lung function.
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FIGURE 1 | Distribution of fungal classes (in % of relative abundance)
in the sputum of healthy individuals (outer ring) and patients with CF
(middle ring) and asthma (inner ring), based on published
pyrosequencing investigations (Delhaes et al., 2012; van Woerden
et al., 2013). The percentages on the legend correspond to each class
identified in healthy, CF, and asthma populations (from the outer to inner
rings respectively). Reads that were not identified as class level are group at
phylum levels (Ascomycota, Basidiomycota). Classes less than 0.1% are
not represented in the rings; the class named “Fungi incertae sedis” refers
to unclassified fungi.
The lung mycobiome of healthy people are comprised var-
ious genus and species principally dominated by environment
agents including Aspergillus species (Figures 1 and 2; Charlson
et al., 2012b; van Woerden et al., 2013; Marsland and Gollwitzer,
2014; Underhill and Iliev, 2014). For example, in the study of
Charlson et al. (2012b), the most common taxa in healthy control
groups are Davidiellaceae, Cladosporium, Eurotium, Penicillium.
Similarly, the most abundant species of van Woerden’s study
(van Woerden et al., 2013) were environmental molds normally
isolated from water, plant, or soil samples such as Cladosporium
cladosporioides and Eremothecium sinecaudum.
The lung mycobiota of diseased subjects has been analyzed
using deep-sequencing approaches for the first time in two stud-
ies conducted in 2012 (Charlson et al., 2012b; Delhaes et al.,
2012). Delhaes et al. (2012) have studied the sputum samples
of CF patients while Charlson et al. (2012b) investigated the
bronchoalveolar lavage (BAL) and oropharyngeal wash (OW)
samples of lung transplant patients suffering previously from
different diseases such as CF, COPD, idiopathic pulmonary fibro-
sis, interstitial lung disease, and cardiovascular disease. In spite
of some differences in the methodology of DNA extractions
and data analysis between the two studies, the most common
species or genera found in the lung mycobiome were: C. albicans,
Aspergillus spp., Penicillium, Cryptococcus, Eurotium, in which
Candida species dominated (Figure 1). It was reported that more
than 60% of the species or genera of the fungal communities iden-
tified using 454 FLX technology (Life Sciences) were not detected
by cultures (Delhaes et al., 2012). These results were recently
confirmed (Willger et al., 2014). Charlson et al. (2012b) also
applied the pyrosequencing method to characterize the airway
microbiome in both the lower and upper respiratory tracts of lung
transplant patients. It was shown that the respiratory microbial
communities in lung transplant recipients differ in structure and
composition from those of healthy subjects which were found to
be similar to the oral microbiome described in another recent
FIGURE 2 | Venn diagram representing the comparison of the
respiratory mycobiomes in healthy individuals, and patients with CF or
asthma from published studies (Delhaes et al., 2012; van Woerden
et al., 2013; Willger et al., 2014). Shared genera are indicated in the
overlap regions. The four most frequent species specifically isolated in each
population are indicated in the non-overlap regions. Genera and species in
red represent known opportunistic pathogens. In healthy people, E.
sinecaudum, Vanderwaltozyma polyspora, and Systenostrema alba are
Saccharomycetaceae and microsporidia isolated from soil and plants with
no known clinical pathogenicity. Cladosporium cladosporioides has been
described in cutaneous, subcutaneous, lung, and disseminated infections in
immunocompromised patients. In the asthma population, Psathyrella
candolleana, Grifola sordulenta, and Termitomyces clypeatus are
environnemental Basidomycota. Malassezia pachydermatis is associated
with atopic dermatitis. In CF patients, exclusively known opportunistic
pathogens are the most frequent: Aspergillus species belonging to the
Fumigata section are responsible for allergic disease (ABPA) as well as
infection, while the pathogenicity of yeasts (Candida and Malassezia) is still
a matter of debate in the context of CF. Among the shared fungal
communities: Eremothecium is a filamentous fungus originally isolated
from cotton; Pseudotaeniolina members are environmental fungi and occur
only rarely in human hosts; Rozella is a widespread genus considered one
of the earliest diverging lineages of fungi, isolated from the environment
(marine); Protomyces is an Ascomycota phytopathogen; Peniophorella are
soil Basidiomycota, of which few species are restricted to the northern
hemisphere; Dioszegia are basidiomycetous yeasts found in a wide range
of habitats; Phlebiopsis are saprotrophic fungi with a widespread
distribution. Cladosporium species are becoming increasingly important
opportunistic pathogens, especially in solid organ transplant recipients.
Malassezia are members of the human skin flora which are associated with
a wide spectrum of clinical manifestations from benign skin conditions
(tinea versicolor) to fungemia in the immunocompromised host, or atopic
dermatitis.
study (Ghannoum et al., 2010). The lower respiratory tract of
lung transplant subjects exhibited higher burdens of bacteria, and
fungi were also detected. The richness and diversity of airway
microbiota and mycobiota were markedly reduced in transplant
subjects compared with control subjects, as well as in CF patients
with decreased lung function and poor clinical status (Charlson
et al., 2012b; Delhaes et al., 2012). In addition, macromycetes
which had been found on the common trees in the forest in
northern France were identified in sputum samples from several
CF patients (Figures 1 and 2). This finding emphasized the signif-
icance of the exposure of the patients to the outdoor environment
(Delhaes et al., 2012; van Woerden et al., 2013).
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Interestingly, the Malassezia genus, which was detected as
abundant taxa in the CF patients (Delhaes et al., 2012; Willger
et al., 2014), was also found in patients with asthma but not in
the control group (van Woerden et al., 2013; Figures 1 and 2).
This genus, which was recently identified as the dominant taxa on
human core body and arms skin (Findley et al., 2013) is known to
be associated with atopic dermatitidis. In addition, pyrosequenc-
ing studies revealed the presence of Malassezia species in oral
cavity (Dupuy et al., 2014) and in sinonasal mucosa of patients
with chronic rhinosinusitis (Cleland et al., 2014). These results
suggest that Malassezia species should have a greater interest in
lung mycobiome research.
Up to now, lung mycobiome exhibited significant composition
differences between patients with CRD and healthy individu-
als according to the limited studies based on next generation
sequencing (NGS) technology (Charlson et al., 2012b; Delhaes
et al., 2012; van Woerden et al., 2013; Willger et al., 2014).
Moreover, the authors were also able to identify the changes in
the lung mycobiota over different time and/or during therapies
administered and correlate these changes with the clinical con-
text. Although the sample size was rather small (eight sputum
samples from four CF patients were studied), Delhaes et al.
(2012) suggested that the respiratory mycobiota plays a role in
the development of CF lung pathology. Candida was the most
commonly genus isolated in CF sputum samples, in particular
C. albicans (Charlson et al., 2012b; Delhaes et al., 2012; Will-
ger et al., 2014). C. albicans has been related to lung function
decline in CF (Chotirmall et al., 2010), even if its pathogenic role
remained controversial. In addition, close interactions between
fungi and bacteria in the lung microbiome of CRD patients have
been proposed (Delhaes et al., 2012; Marsland and Gollwitzer,
2014), in agreement with the recent ecological model of CF
lungs, named the “climax-attack” community (Conrad et al.,
2013). In this model, climax communities are composed of persis-
tent bacterial and fungal populations (for example Pseudomonas
aeruginosa, Staphylococcus aureus, Aspergillus spp., Scedosporium
spp.) which colonize the airway during the stable periods. The
attack communities are more virulent, usually composed of
pathogenic microorganisms which are associated with pulmonary
exacerbations such as S. pneumoniae, H. influenza, Rhinovirus,
Adenovirus, etc.). Both attack and climax communities can coex-
ist in CF patients’ lungs and together contribute to the lung
function decline. In this model, the climax community seems
to be able to avoid the patients’ immune responses and/or is
more resistant to broad-spectrum antibiotic therapy. In contrast,
the attack communities are expected to be more susceptible to
antibiotics.
This model or other mathematical modeling together with
metagenomic methods could help predict the effects of antimi-
crobial treatments on the lung microbiome, leading to a more
effective use of antibiotic and/or antifungal drugs with different
treatment regimens. On the whole, these findings provide novel
approaches to addressing the relationship between microbial
communities and pulmonary disease. It could help to assess
lung infections by favoring the development of new therapeutic
approaches and models. More investigations should be carried
on this field to improve our knowledge of the role of the myco-
biome in the lung microbiome and in chronic diseases, such
as CRD.
RELATIONSHIPS BETWEEN THE LUNG AND GUT
MICROBIOMES: FOCUS ON THE MYCOBIOME
Despite limited research data, the concept of a relationship
between the respiratory and gut microbiomes has recently been
considered (Duytschaever et al., 2011; Madan et al., 2012; Huang,
2013). The human gastrointestinal tract is colonized by a complex
microbial community, which has been extensively studied during
the last decade. The gastrointestinal microbiome is now consid-
ered an organ with an important role in digestive metabolism, in
the development and homeostasis of host inflammatory immune
responses. Dysbiosis of the gut microbiome has been associated
with a variety of chronic diseases, such as inflammatory bowel
disease, obesity, type 2 diabetes, and asthma (Turnbaugh and
Gordon, 2009; Huang, 2013; Karlsson et al., 2013). Furthermore,
there is increasing evidence that the gastrointestinal mucosa is
a predominant site of microbiome–host interactions and can
contribute to the development of immune responses at distal
mucosal sites.
Due to ethical considerations, the small size of samples, and/or
technical problems, studies conducted on human beings to inves-
tigate the relationships between the gut and lung microbiomes
are limited. However, animal models have been developed to
test the influence of the gut microbiome on the lung micro-
biome and immunity. Using a mouse model of cefoperazone-
induced gastrointestinal microbiome disruption, Noverr et al.
(2004, 2005) demonstrated that the gastrointestinal dysbiosis
was characterized by increased numbers of enteric bacteria and
C. albicans. They also proved the impact of the gastrointestinal
microbiome perturbation on immune responses in the lung. Only
mice with altered gastrointestinal microbiota developed airway
allergic responses to intranasal administration of ovalbumin,
associated with significant increases in the levels of eosinophils,
mast cells, interleukin (IL)-5 and IL-13, INFγ in the lungs,
and IgE in serum. The eosinophilic nature of the inflammatory
response was confirmed by lung histological analysis. The allergic
response was also induced by intranasally delivered conidia of
A. fumigatus using the same model to perturb the gut microbiome
either in Balb/c or C57BL/6 mice. These studies demonstrated
that the effects of gastrointestinal microbiome disruption were
independent of the host genetic background, and that the airway
allergic responses following this dysbiosis were independent of
the nature of the allergen challenge but require IL-13 production
in mouse models (Noverr et al., 2004, 2005). A more recent
study (Barfod et al., 2013) compared the bacterial communities
isolated from BAL fluids, lung tissue biopsies, fecal samples, and
vaginal lavage fluids of BALB/c mice. It has shown that the lung
microbiota is distinct from the cecal microbiota but overlaps
with the vaginal microbiota in this animal model. Barfod et al.
(2013) recommended taking into account the lung microbiome
and mycobiome when studying the pathogenesis of inflammatory
lung diseases.
To date, only two clinical trials have been conducted in
CRD populations to document the relationships between
the gut microbiome and the lungs (Duytschaever et al., 2011;
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Madan et al., 2012). Twenty-one children with CF and 24 healthy
siblings were included in a cross-sectional study (Duytschaever
et al., 2011) in an effort to find any significant differences between
the relative composition and temporal stability of the predomi-
nant fecal microbiome in CF patients and those in their healthy
siblings, using culture and DGGE methods. Siblings were chosen
as controls for patients with CF to avoid the effects of several
factors that may influence the composition of the gastrointestinal
microbiota, such as genetic background, age, and environmental
factors. However, other factors, including antibiotic management
in CF or the effect of daily diet, certainly differed since patients
with CF are recommended to consume a high-fat diet to meet
their energy needs. While enterobacterial counts were consistently
higher in CF patients, no typical DGGE fingerprints were found
from the cross-sectional study. The longitudinal study performed
on two patient–sibling pairs exhibited a trend toward lower
temporal stability and richness in the fecal microbiome of CF
patients. Both cross-sectional and longitudinal studies provided
primary evidence of a continuous state of intestinal dysbiosis in
CF children compared to their siblings. Both the intrinsic char-
acteristics of the disease (such as abnormal mucus secretions and
pancreatic insufficiency) and the detrimental effects of intensive
antimicrobial treatment courses most likely play key roles in this
dysbiosis.
The second study, using the 16 rDNA gene pyrosequencing
(Madan et al., 2012), investigated the respiratory and intestinal
microbiota development in infants with CF followed from birth
to 21 months. In observing the dominant genera, some similar
bacteria were found in both gut and respiratory microbiota,
such as Veillonella and Streptococcus. Bacterial diversity increased
significantly over time in both the respiratory and intestinal tracts,
and in which the respiratory microbiota increased more rapidly.
A significant proportion of bacteria increasing in the gut were also
increasing in the respiratory tract. Furthermore, changes in diet
(such as breast-feeding or introduction of solid foods) also result
in modified microbiomes, suggesting an authentic link between
nutrition and the development of a microbial lung community
(Madan et al., 2012). These data suggest that gut colonization
patterns and nutritional factors play key roles in the development
of the respiratory microbiome.
Changes in the intestinal microbiome also reflect changes
in the oropharyngeal microbiome (including the mycobiome
component), which may directly influence the respiratory micro-
biome and host immune response through microaspiration
(Charlson et al., 2012b). The mycobiota of the oral cavity in
healthy individuals has been well characterized (Ghannoum et al.,
2010; Dupuy et al., 2014). Among the 15 genera identified and
composed of cultivable and non-cultivable species, Candida [iso-
lated from 75% of all study participants (Ghannoum et al., 2010)],
Aspergillus, Fusarium, and Cryptococcus were predominant. More
recently, a high prevalence and abundance of the genus Malassezia
was discovered by revising current practices in sequence-based
taxonomy assignments (Dupuy et al., 2014). Like the oral bacterial
microbiome, the oral mycobiome exhibited great variation within
and between individuals that may influence the respiratory and
intestinal mycobiomes in healthy individuals as well as in patients
(Noverr et al., 2004, 2005; Aas et al., 2005; Ghannoum et al.,
2010; Kieninger et al., 2013; Dupuy et al., 2014; Mukherjee et al.,
2014).
Altogether, these studies support the concept that the indige-
nous microbiome and mycobiome of the gastrointestinal tract
have a profound influence on the development and maintenance
of the respiratory microbiome, as well as lung immunity and
inflammation. Further studies targeting intestinal–respiratory
microbiome interactions are likely to yield important insights
into the dynamics and homeostasis of microbiomes, consequently
yielding a better understanding of how intestinal dysbiosis may
have notable functional consequences in the pathogenesis of CRD.
These findings will represent opportunities for establishing the
clinical relevance of early intervention in CRD with altered dietary
or frequent antibiotic therapy that may contribute to the develop-
ment of dysbiosis, or probiotic strategies that might change the
colonization of the gut plus lung and thereby improve patients’
outcomes. As this field advances over the next several years, we
anticipate that studies using larger cohorts, control groups such as
siblings, multicenter designs, and longitudinal sampling will add
to our knowledge of the lung microbiome and mycobiome.
OUTLOOKS: THE RESPIRATORY MYCOBIOME OR A
FORGOTTEN PLAYER THAT DESERVES OUR ATTENTION?
Next generation sequencing technologies provide the opportunity
to simultaneously analyze the microbial community (bacteria,
viruses, and fungi) as a whole in an integrative research method-
ology without a priori knowledge of existing microorganisms,
and consequently represent the most promising investigational
strategy in the context of CRD (Figure 3). In the last half decade,
interest in the human lung bacteriome and its role in developing
CRD have increased substantially. As in the intestinal micro-
biome, bacteria are certainly the most represented microorgan-
isms of the respiratory microbiome, but Archaea, viruses (includ-
ing phages), and Eukaryota (including fungi) also formed part of
this respiratory microbiome, and may reveal clinical significances
especially when dysbiosis occurs. However, little to nothing is
known about the role of fungi in establishing and maintaining a
healthy respiratory ecosystem, or on the other hand in facilitating
pulmonary diseases. In agreement with recent published data
(Findley et al., 2013; Huffnagle and Noverr, 2013), fungi may
FIGURE 3 | Integrative research based on the lung mycobiome, virome,
and bacteriome.
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play an important role in the stability of the human microbial
community, thus affecting human health and disease.
Given the significantly increased rate of allergic diseases such
as asthma in the westernized countries, understanding the role of
the lung microbiome especially the mycobiome will be of interest
in coming decades. In addition, there is evidence that the fungal
exposure is associated with asthma and chronic inflammatory
pulmonary diseases (Reponen et al., 2011, 2012; Hulin et al., 2013;
Kieninger et al., 2013; Pringle, 2013). Fungi are also potential
pathogens of the lungs while they probably act as commensals
in the gastrointestinal tract, making the mycobiome analysis
valuable, or even higher in the respiratory tract.
When considering the respiratory microbiome as a complex
and continuous polymicrobial ecosystem composed of viruses,
bacteria, and fungi (as a parallel from Island biogeography
recently proposed by Whiteson et al. (2014)), these microor-
ganisms may have mutual interferences. Unfortunately, their
co-occurrence in the lung microbiome is poorly appreciated. To
date, few studies underlined the impact of cross-kingdom synergy
between bacteria and fungus in the respiratory tract and the
sinonasal mucosa (Delhaes et al., 2012; Boase et al., 2013; Cleland
et al., 2014). The limited understanding of fungal–bacterial inter-
actions and their function in respiratory diseases and healthy
lungs results primarily from our incomplete knowledge of the
respiratory mycobiome. Overall, information obtained from oral
cavity and gastrointestinal ecosystems indicates that fungi influ-
ence bacterial behavior through different interactions (i.e., pos-
itive and negative influences between and among microbiome
members; Duran-Pinedo et al., 2011, 2014; Iliev et al., 2012). As
in other body sites, the interactions between fungi and bacteria
may occur in the lungs at physical and chemical levels. The
physical interactions are mainly represented by co-occurrence or
co-exclusion phenomena, while the chemical interactions include
metabolic needs, quorum-sensing exchanges, and the production
of antimicrobial agents. Fungi and bacteria are able to generate
biofilm structures which protect bacteria and/or fungi against
desiccation, antibiotic diffusion, or immune cell attacks. It results
in the development of strains that are multiresistant to antimi-
crobial agents and able to disseminate. Co-infection by these
pathogens forming mixed communities has elevated virulence
and resistance, and resilience properties that are significantly
different from those of single-species communities (reviewed in
Wargo and Hogan, 2006). Animal models have also shown the
impact of cross-kingdom synergy between bacteria and fungi,
supporting a potentially mutualistic partnership between Can-
dida and Streptococcus (Roux et al., 2009; Diaz et al., 2012; Mason
et al., 2012; Xu et al., 2014).
By comparing cross-kingdom relationships associated with
health and CRD using in vitro and in vivo studies, “omics”
approaches will revolutionize the identification and characteriza-
tion of fungal–bacterial interactions. Correlation network infor-
mation already allowed authors to identify Prevotella species as
growth co-partners of Tannerella sp. HOT286 and consequently
to cultivate the uncultivated Tannerella bacteria in a co-culture
system (Duran-Pinedo et al., 2011). Other authors revealed signif-
icant inter-bacteria associations at different body sites of healthy
people (Faust et al., 2012). By exploring co-occurrence patterns
of fungi and bacteria, Mukherjee et al. (2014) identified and
explored antagonisms between Candida and Pichia yeasts in oral
rinse samples. Furthermore, these bacterial–fungal interactions
often have an important impact on the biology of the host
metabolism and immunity as demonstrated in the gut micro-
biome (reviewed in Ianiro et al., 2014; Underhill and Iliev, 2014);
they might also play a role in chronic pulmonary diseases and the
pulmonary transplantation system, which emphasizes the need to
define the respiratory mycobiome.
CONCLUSION AND FUTURE DIRECTIONS
For a few decades, metagenomic research has focused on the
bacterial microbiome; however, clinical and experimental studies
have started to highlight a role for fungi in the human micro-
biome in general, and in the respiratory microbiome in particular.
Such a polymicrobial community has emergent properties that
cannot be inferred by studying its components separately. In this
respect, the “omics” approaches will be significantly helpful in
identifying and deciphering candidate fungal–bacterial interac-
tions essential to maintaining a healthy respiratory microbiome,
or on the other hand to facilitate CRD.
The rapid development of NGS technologies has opened up
possibilities to better define in a novel way, the compositions
and functions of the respiratory mycobiome and microbiome
in homeostasis, during infection, and in the context of CRD.
It is now essential to develop robust universal methodological
strategies, and to implement large multicenter studies. In spite
of recent methodological advances, the current metagenomic
approaches used to study the mycobiome still have certain lim-
itations. As proposed by Diaz et al. (2014), there are numerous
pitfalls associated with the mycobiome that we need to challenge
collectively. First, fungal cells are notoriously difficult to break
open and might require chemical or mechanical lysis as a pre-
extraction step (Chen et al., 2002; Fredricks et al., 2005; Griffiths,
2006; Plassart et al., 2012; Dupuy et al., 2014; Goldschmidt et al.,
2014). Another technical point in measuring fungi using a DNA
based method, is to be able to distinguish the DNA of living
microorganisms and that of dead ones. Several recent studies
(Nocker and Richter-Heitmann, 2010; Rogers et al., 2013; Chiao
et al., 2014; Cuthbertson et al., 2014) demonstrated that a sample
pre-treatment with propidium monoazide (a chemical molecule
able to penetrate exclusively into cells with an intact membrane
which are considered as viable cells) modified the bacterial com-
munity profiles obtained by NGS. The second challenge is to
improve the taxonomic assignment quality by establishing an
accurate updated fungal database. Since the internal transcribed
spacer (ITS) regions of the rDNA are widely used for fungal
species identification and recently formalized as universal DNA
barcode markers for fungi (Delhaes et al., 2012; Schoch et al.,
2012), several projects have been conducted to develop fungal
databases, such as ITSDB or UNITE for QIIME released3 (Diaz
et al., 2014) or ISHAM ITS Database4. The later ITS database was
recently generated from quality controlled ITS sequences, which
represent the actual sequence variation found in each species.
3http://qiime.org/home_static/dataFiles.html
4http://its.mycologylab.org/
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Given that fungi represent the largest family of microorganisms
with multiple names, another challenge is to prevent unnecessary
nomenclatural flux, as recently proposed (de Hoog et al., 2014).
In this context, the ISHAM ITS or UNITE databases represent a
nice opportunity to create an accurate database with consensual
nomenclature. Further advances in data generation and analy-
sis are also required to minimize errors and misinterpretations,
to make cross-studies and multicenter trials more feasible, and
finally to link the bench and the clinic.
To understand the biological function of the respiratory myco-
biome in host inflammatory lung responses, its implication in
CRD progression, its role in local cross-kingdom microbial inter-
actions, as well as in the cross-talk between the intestinal and
lung microbiomes, future large-scale cross-sectional and longi-
tudinal studies must be conducted to answer these questions
raised. By analogy to the microbiota signatures recently proposed
for assessing responses to dietary interventions in obese indi-
viduals (Korpela et al., 2014) and for predicting future exac-
erbations in bronchiectasis (Rogers et al., 2014), determining
both specific mycobiota and microbiota respiratory signatures
could be useful for prophylactic or therapeutic management in
CRD. These microbiome and mycobiome signatures might also
serve as specific biomarkers preceding the clinical manifesta-
tions of disease (CRD), which should be more sensitive than
routine culture methods. They might then be an indicator for
timely clinical intervention and successful disease management
(Lim et al., 2014). The goal is to establish both the mycobiome
and microbiome in the respiratory tract over time during a
respiratory superinfection or an acute pulmonary exacerbation,
in order to provide key elements (signatures, dysbiosis) for
early diagnosis and appropriate preventive therapy of secondary
infections. Longitudinal studies will help in analyzing fungal–
bacterial interactions simultaneously during the CRD progression
and therapy outcome. All these additional studies are needed
to generate hypotheses that in vitro and animal models will
explore.
By taking into account the total respiratory microbiome (that
does not only consist of bacteria but also fungi, phages and
viruses), these future studies will be dramatically instrumental
in improving our knowledge of the pathogenesis of CRD and in
developing innovative therapies.
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